Christopher P Mill

12PUBLICATIONS
25CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsMechatronics hardware design and architectureRegenerative medicine (incl. stem cells)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Feb 24, 2026
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.

Warren Fiskus, Christopher P Mill, Ghayas C Issa

|Dec 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.

Christine E Birdwell, Warren Fiskus, Christopher P Mill

|Aug 19, 2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Warren Fiskus, Lucia Masarova, Christopher P Mill

|Mar 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Warren Fiskus, Christopher P Mill, Jessica Piel

|Nov 19, 2024
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Warren Fiskus, Christopher P Mill, Prithviraj Bose

|Mar 04, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.

Warren Fiskus, Jessica Piel, Mike Collins

Pageof 2

Frequent Collaborators

12 joint publications

Warren Fiskus

12 joint publications

Courtney DiNardo

9 joint publications

Naval G Daver

9 joint publications

Sanam Loghavi